

# Caterina Ilari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4799522/publications.pdf>

Version: 2024-02-01

325  
papers

9,593  
citations

66343

42  
h-index

48315

88  
g-index

329  
all docs

329  
docs citations

329  
times ranked

11392  
citing authors

#	ARTICLE	IF	CITATIONS
1	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. <i>Haematologica</i> , 2022, 107, 868-876.	3.5	31
2	Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia. <i>Haematologica</i> , 2022, 107, 334-337.	3.5	4
3	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	2.5	20
4	INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 1742-1753.	5.2	33
5	Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	1.3	0
6	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	5
7	Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. <i>Haematologica</i> , 2022, 107, 1470-1473.	3.5	12
8	Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	1
9	Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1003-1015.	2.4	2
10	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. <i>Frontiers in Oncology</i> , 2022, 12, 839915.	2.8	10
11	Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. <i>Haematologica</i> , 2022, 107, 2356-2364.	3.5	6
12	Continuous treatment with ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	14
13	Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries. <i>British Journal of Haematology</i> , 2022, 196, 849-863.	2.5	2
14	Efficacy of Front-Line ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. <i>Cancers</i> , 2022, 14, 207.	3.7	3
15	COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. <i>Haematologica</i> , 2022, 107, 1955-1959.	3.5	6
16	Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall. <i>British Journal of Haematology</i> , 2022, 198, .	2.5	3
17	Immuno-hematological monitoring after allogeneic stem cell transplantation: a single-center, prospective study of 104 patients.. <i>Blood Transfusion</i> , 2022, , .	0.4	0
18	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2022, 386, 2399-2411.	27.0	31

#	ARTICLE	IF	CITATIONS
19	Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 893-900.	2.8	7
20	Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab. <i>Annals of Hematology</i> , 2021, 100, 2117-2119.	1.8	4
21	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021, 35, 235-238.	7.2	17
22	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021, 106, 1559-1568.	3.5	49
23	Very late acute myeloid leukemia relapse: clinical features, treatment and outcome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1022-1025.	1.3	2
24	Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 755-757.	1.3	6
25	Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103163.	4.4	10
26	Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 828-836.	1.3	11
27	Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL1308 trial. <i>American Journal of Hematology</i> , 2021, 96, 292-301.	4.1	21
28	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021, 62, 1026-1027.	1.3	4
29	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	2.2	5
30	A multicenter total therapy strategy for <i>de novo</i> adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. <i>Haematologica</i> , 2021, 106, 1828-1838.	3.5	33
31	Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. <i>HemaSphere</i> , 2021, 5, e543.	2.7	20
32	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	4.1	10
33	Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study. <i>British Journal of Haematology</i> , 2021, 193, 325-338.	2.5	6
34	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Leukemia</i> , 2021, 35, 2232-2242.	7.2	6
35	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2261-2266.	1.3	0
36	Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. <i>Hematological Oncology</i> , 2021, 39, 326-335.	1.7	8

#	ARTICLE	IF	CITATIONS
37	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1213-1219.	1.8	4
38	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 637186.	2.8	17
39	<i>TP53</i> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	4.1	8
40	The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. <i>British Journal of Haematology</i> , 2021, 194, 78-82.	2.5	8
41	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab+bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	4.1	3
42	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	1.4	30
43	Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients – a 25-year Italian experience. <i>British Journal of Haematology</i> , 2021, 195, 278-283.	2.5	4
44	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	3.7	16
45	Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. <i>Blood</i> , 2021, 138, 2290-2293.	1.4	15
46	Introduction Chronic Lymphocytic Leukemia. Where Do We Stand, Where Do We Go. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 257-258.	2.0	0
47	Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 320-327.	2.0	2
48	Myeloid Sarcoma: Diagnostic and Treatment Tools from a Monocentric Retrospective Experience. <i>Acta Haematologica</i> , 2021, , 1-5.	1.4	3
49	COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 328-333.	2.0	7
50	Emerging tyrosine kinase inhibitors for the treatment of adult acute lymphoblastic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 281-294.	2.4	3
51	Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. <i>Hematological Oncology</i> , 2021, 39, 570-574.	1.7	9
52	Treatment of childhood acute lymphoblastic leukemia in Iraq: a 17-year experience from a single center. <i>Leukemia and Lymphoma</i> , 2021, 62, 3430-3439.	1.3	3
53	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684621.	2.8	6
54	Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. <i>Hematological Oncology</i> , 2021, 39, 680-686.	1.7	12

#	ARTICLE	IF	CITATIONS
55	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. <i>Blood</i> , 2021, 138, 2727-2730.	1.4	9
56	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	1.8	14
57	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
58	Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. <i>Haematologica</i> , 2021, 106, 1500-1503.	3.5	7
59	Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae. <i>BMC Infectious Diseases</i> , 2021, 21, 1079.	2.9	4
60	Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 3755-3755.	1.4	0
61	Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study. <i>Blood</i> , 2021, 138, 3408-3408.	1.4	1
62	A Predictive Endothelial-Leukemia Pre-Clinical Platform to Uncover Drug Vulnerabilities for Personalized Treatments. <i>Blood</i> , 2021, 138, 704-704.	1.4	0
63	Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 804714.	2.8	9
64	Increased eryptosis in patients with primary antiphospholipid syndrome (APS): a new actor in the pathogenesis of APS. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 838-843.	0.8	1
65	Does MRD have a role in the management of iNHL?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 320-330.	2.5	4
66	Platelet activation and multidrug resistance protein-4 expression in children and adolescents with different subtypes of primary thrombocythemia. <i>Haematologica</i> , 2020, 105, e65-e67.	3.5	1
67	Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with <i>Bcr-Abl</i> fusion transcript. <i>Leukemia and Lymphoma</i> , 2020, 61, 469-472.	1.3	12
68	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	1.7	21
69	Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy. <i>British Journal of Haematology</i> , 2020, 188, 249-258.	2.5	16
70	HIF-1 $\alpha$ is over-expressed in leukemic cells from <i>p53</i> -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	3.5	39
71	Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2020, 34, 441-450.	7.2	8
72	Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients. <i>HIV Medicine</i> , 2020, 21, e7.	2.2	2

#	ARTICLE	IF	CITATIONS
73	Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients. Supportive Care in Cancer, 2020, 28, 4193-4199.	2.2	20
74	The role of cladribine in acute myeloid leukemia: an old drug up to new tricks. Leukemia and Lymphoma, 2020, 61, 536-545.	1.3	8
75	Dasatinibâ€“Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. New England Journal of Medicine, 2020, 383, 1613-1623.	27.0	279
76	Favorable outcome of chronic myeloid leukemia coâ€“expressing e13a2 and e14a2 transcripts, treated with nilotinib. Hematological Oncology, 2020, 38, 607-610.	1.7	1
77	COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome. Acta Haematologica, 2020, 143, 574-582.	1.4	14
78	The advantages and risks of ruxolitinib for the treatment of polycythemia vera. Expert Review of Hematology, 2020, 13, 1067-1072.	2.2	8
79	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€“world setting. A GIMEMAâ€“ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
80	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. Hematological Oncology, 2020, 38, 698-704.	1.7	3
81	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisibâ€“rituximab. Blood Cancer Journal, 2020, 10, 92.	6.2	7
82	A Rare Case of Coexisting Breast Cancer and Refractory Acute Myeloid Leukemia. Case Reports in Hematology, 2020, 2020, 1-4.	0.4	1
83	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. Annals of Hematology, 2020, 99, 2405-2416.	1.8	11
84	Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. Expert Review of Hematology, 2020, 13, 1311-1318.	2.2	6
85	Philadelphiaâ€“positive acute lymphoblastic leukaemia (ALL) in Italy during the COVIDâ€“19 pandemic: a Campus ALL study. British Journal of Haematology, 2020, 190, e3-e5.	2.5	27
86	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood, 2020, 135, 1859-1869.	1.4	86
87	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. Annals of Hematology, 2020, 99, 2773-2777.	1.8	2
88	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. Annals of Hematology, 2020, 99, 1525-1530.	1.8	9
89	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. Blood Cancer Journal, 2020, 10, 66.	6.2	6
90	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report. Blood, 2020, 136, 763-766.	1.4	33

#	ARTICLE	IF	CITATIONS
91	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	7.2	57
92	Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 189, 826-843.	2.5	26
93	Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 629-639.	2.8	18
94	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
95	Effect of low or high doses of low-molecular-weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e214-e218.	2.5	25
96	ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 190, e346-e349.	2.5	6
97	First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an "operational cure". <i>Lancet Haematology</i> , 2020, 7, e182-e183.	4.6	0
98	Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, e101-e105.	2.5	5
99	High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). <i>Haematologica</i> , 2020, 105, 2671-2674.	3.5	1
100	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	3.5	64
101	Pharmacokinetics of Nilotinib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 812-820.	7.0	23
102	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020, 189, 853-859.	2.5	18
103	"Miro" Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, e20073-e20073.	1.6	1
104	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	1.4	1
105	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020, 136, 23-25.	1.4	0
106	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	1.4	0
107	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
108	Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. I Training/Validation Study. <i>Blood</i> , 2020, 136, 31-32.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	1
110	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	1.4	0
111	Complex Karyotype Subtypes at Chronic Lymphocytic Leukemia Diagnosis Refine the Risk of Developing a Richter Syndrome. the Richter Syndrome Scoring System. <i>Blood</i> , 2020, 136, 33-34.	1.4	1
112	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
113	Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects. <i>Blood</i> , 2020, 136, 37-37.	1.4	0
114	Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease. <i>Leukemia and Lymphoma</i> , 2019, 60, 274-276.	1.3	3
115	Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. <i>Frontiers in Oncology</i> , 2019, 9, 726.	2.8	85
116	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2388-2397.	2.0	33
117	Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e217-e219.	2.5	1
118	Maintenance therapy in AML: The past, the present and the future. <i>American Journal of Hematology</i> , 2019, 94, 1254-1265.	4.1	56
119	Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019, 37, 368-374.	1.7	13
120	Digital droplet PCR at the time of TKI discontinuation in chronic phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. <i>Hematological Oncology</i> , 2019, 37, 652-654.	1.7	17
121	DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019044.	1.3	16
122	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	1.7	13
123	Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience. <i>British Journal of Haematology</i> , 2019, 187, e8-e11.	2.5	14
124	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	3.7	16
125	Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment. <i>Leukemia Research</i> , 2019, 87, 106233.	0.8	16
126	Incidence of Clinically Significant ( $\geq 10$ g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib. <i>Oncology Research and Treatment</i> , 2019, 42, 660-664.	1.2	2



#	ARTICLE	IF	CITATIONS
127	Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?. <i>Frontiers in Oncology</i> , 2019, 9, 689.	2.8	41
128	CMV MANAGEMENT WITH SPECIFIC IMMUNOGLOBULINS: A MULTICENTRIC RETROSPECTIVE ANALYSIS ON 92 ALLOTRANSPLANTED PATIENTS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019048.	1.3	9
129	Another step forward in the 20-year history of <i>IGHV</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 219-221.	3.5	11
130	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. <i>Annals of Hematology</i> , 2019, 98, 1933-1936.	1.8	5
131	The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia. <i>British Journal of Cancer</i> , 2019, 121, 150-156.	6.4	31
132	Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice. <i>Annals of Hematology</i> , 2019, 98, 1919-1925.	1.8	8
133	Atypical Chronic Myeloid Leukemia in a Patient with Aplastic Anemia. <i>Acta Haematologica</i> , 2019, 142, 185-186.	1.4	1
134	Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 2053-2060.	3.5	60
135	Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life. <i>Annals of Hematology</i> , 2019, 98, 1891-1904.	1.8	10
136	Long-term results with the adapted LMB 96 protocol in children with B-cell non Hodgkin lymphoma treated in Iraq: comparison in two subsequent cohorts of patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 1224-1233.	1.3	6
137	Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. <i>Hematological Oncology</i> , 2019, 37, 291-295.	1.7	14
138	Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2838-2840.	1.3	24
139	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	1.8	10
140	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	1.7	19
141	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	1.7	3
142	The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of MYH9 syndrome treated with a TPO-RA. <i>Haemophilia</i> , 2019, 25, e288-e290.	2.1	2
143	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	1.7	53
144	RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019024.	1.3	6

#	ARTICLE	IF	CITATIONS
145	Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. <i>Hematology</i> , 2019, 24, 337-348.	1.5	48
146	Response to Comment by Amato T. <i>et al.</i> <i>Haematologica</i> , 2019, 104, e541-e541.	3.5	0
147	THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL. <i>Hematological Oncology</i> , 2019, 37, 110-111.	1.7	17
148	Aplastic Anemia and Good Syndrome in a Heavily Treated Stage IV Thymoma Patient: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2019, 2019, 1-6.	0.4	5
149	<i>IL7R</i> overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies. <i>Leukemia and Lymphoma</i> , 2019, 60, 829-832.	1.3	10
150	Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 312-318.	3.5	54
151	<i>BCR/ABL1</i> -like acute lymphoblastic leukemia: How to diagnose and treat?. <i>Cancer</i> , 2019, 125, 194-204.	4.1	51
152	Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. <i>Expert Review of Hematology</i> , 2019, 12, 81-87.	2.2	11
153	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 798-809.	2.4	106
154	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	1.8	10
155	Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial. <i>Blood</i> , 2019, 134, 740-740.	1.4	30
156	Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 2888-2888.	1.4	2
157	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019, 134, 3010-3010.	1.4	0
158	Treatment of Adults with Minimal Residual Disease (MRD) Positive Acute Lymphoblastic Leukemia with Blinatumomab in a Real-World Setting: Results from the Neuf Study. <i>Blood</i> , 2019, 134, 2624-2624.	1.4	1
159	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019, 134, 3845-3845.	1.4	1
160	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	1.7	55
161	Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia. <i>Current Oncology Reports</i> , 2018, 20, 23.	4.0	19
162	Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. <i>Leukemia and Lymphoma</i> , 2018, 59, 2715-2718.	1.3	2

#	ARTICLE	IF	CITATIONS
163	Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review. <i>Haematologica</i> , 2018, 103, e138-e140.	3.5	4
164	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018, 97, 1577-1580.	1.8	32
165	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	3.5	30
166	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018, 32, 1869-1873.	7.2	8
167	In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. <i>British Journal of Haematology</i> , 2018, 181, 229-233.	2.5	34
168	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	4.1	26
169	High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement. <i>Leukemia</i> , 2018, 32, 1807-1810.	7.2	20
170	Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. <i>Annals of Oncology</i> , 2018, 29, 966-972.	1.2	19
171	Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. <i>Oncolimmunology</i> , 2018, 7, e1341032.	4.6	11
172	Comparison between the CLLâ€PI and the <sc>B</sc>arcelonaâ€<sc>B</sc>rno prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , 2018, 93, E35-E37.	4.1	18
173	Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. <i>Leukemia</i> , 2018, 32, 543-546.	7.2	4
174	Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia. <i>European Journal of Internal Medicine</i> , 2018, 58, 22-27.	2.2	3
175	Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience. <i>Acta Haematologica</i> , 2018, 140, 105-111.	1.4	5
176	Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events. <i>Annals of Hematology</i> , 2018, 97, 1803-1808.	1.8	18
177	Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. <i>Blood</i> , 2018, 132, 405-412.	1.4	46
178	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 601-611.	2.2	10
179	Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy. <i>Annals of Hematology</i> , 2018, 97, 1797-1802.	1.8	20
180	Current and future therapeutic approaches for the treatment of follicular lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 931-941.	2.4	0

#	ARTICLE	IF	CITATIONS
181	Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia. <i>Cancer Immunology Research</i> , 2018, 6, 1110-1119.	3.4	8
182	Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. <i>Haematologica</i> , 2018, 103, 1889-1898.	3.5	19
183	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018, 93, E216-E219.	4.1	15
184	Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study. <i>Leukemia</i> , 2018, 32, 1778-1786.	7.2	28
185	Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?. <i>European Journal of Haematology</i> , 2018, 101, 578-584.	2.2	3
186	Clinical Significance of Occult Central Nervous System Disease in Adult ACUTE Lymphoblastic Leukemia. a Multicenter, Report from the Campus ALL/Gimema Network. <i>Blood</i> , 2018, 132, 658-658.	1.4	3
187	Protective Role Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia: FOCUS on Subcutaneous Immunoglobulin Formulations. <i>Blood</i> , 2018, 132, 4954-4954.	1.4	3
188	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	1.4	6
189	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	1.4	2
190	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	1.4	11
191	A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression. <i>Blood</i> , 2018, 132, 1834-1834.	1.4	1
192	Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome. <i>Blood</i> , 2018, 132, 4256-4256.	1.4	1
193	Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. <i>Oncotarget</i> , 2018, 9, 7534-7540.	1.8	19
194	AB0163â€¦Increased eryptosis levels in erythrocytes treated with antibodies from aps patients: eryptosis as new actor in aps pathogenesis. , 2018, , .		0
195	Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?. <i>Blood</i> , 2018, 132, 1746-1746.	1.4	0
196	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	1.4	0
197	Identification of Predictive Factors for Overall Survival at Baseline and during Azacitidine Treatment in High-Risk Myelodysplastic Syndromes Treated in the Clinical Practice. <i>Blood</i> , 2018, 132, 5518-5518.	1.4	0
198	Overall Survival and Response Rates after a 10-Year Follow-up of Chronic Myeloid Leukemia Patients in Chronic Phase Treated with Imatinib in a Real-Life Practice. <i>Blood</i> , 2018, 132, 1741-1741.	1.4	0

#	ARTICLE	IF	CITATIONS
199	The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 1844-1844.	1.4	0
200	Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group. <i>Blood</i> , 2018, 132, 5634-5634.	1.4	0
201	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. <i>Blood</i> , 2018, 132, 5464-5464.	1.4	0
202	Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib+dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. <i>Leukemia</i> , 2017, 31, 997-1000.	7.2	64
203	Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 529-535.	4.1	20
204	Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2017, 57, 65-71.	0.8	17
205	Diffuse large B-cell lymphoma genotyping on the liquid biopsy. <i>Blood</i> , 2017, 129, 1947-1957.	1.4	183
206	Comparative analysis between <i>RQ</i> and digital droplet <i>PCR</i> of <i>BCL2/IGH</i> gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 177, 588-596.	2.5	39
207	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1530-1536.	3.5	15
208	Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 2552-2559.	7.2	16
209	Management of CLL in the elderly. <i>Annals of Oncology</i> , 2017, 28, 200-204.	1.2	1
210	BCR-ABL specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. <i>Blood</i> , 2017, 129, 582-586.	1.4	49
211	Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e534-e543.	4.6	31
212	Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. <i>Advances in Therapy</i> , 2017, 34, 2232-2273.	2.9	407
213	Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. <i>American Journal of Hematology</i> , 2017, 92, E668-E670.	4.1	7
214	Clinical relevance of silent red blood cell autoantibodies. <i>Haematologica</i> , 2017, 102, e473-e475.	3.5	9
215	The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, E661-E664.	4.1	14
216	Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. <i>Expert Review of Hematology</i> , 2017, 10, 761-774.	2.2	14

#	ARTICLE	IF	CITATIONS
217	Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1473-1484.	4.2	45
218	Very late relapse in a patient with acute promyelocytic leukemia (APL) rescued with a chemotherapy-free protocol. <i>Leukemia and Lymphoma</i> , 2017, 58, 999-1001.	1.3	6
219	Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia. <i>Hematological Oncology</i> , 2017, 35, 804-809.	1.7	5
220	<sc>TPO</sc>â€<sc>RA</sc>s in <sc>pITP</sc>: description of a case series and analysis of predictive factors for response. <i>European Journal of Haematology</i> , 2017, 98, 242-249.	2.2	14
221	Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase II GIMEMA trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 1640-1647.	1.3	8
222	ABO150â€...Increased eryptosis levels in primary antiphospholipid syndrome patients. , 2017, , .		0
223	First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 99-99.	1.4	63
224	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. <i>Oncotarget</i> , 2017, 8, 25455-25468.	1.8	10
225	COSMOS: MOR208 plus idelalisib or venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi)â€”A two-cohort phase II study.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7567-TPS7567.	1.6	0
226	Life-threatening autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura: successful selective splenic artery embolization. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016020.	1.3	2
227	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016, 7, 13886-13901.	1.8	20
228	Comparative analysis between RQâ€PCR and digitalâ€dropletâ€PCR of immunoglobulin/Tâ€cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 541-549.	2.5	59
229	Severe Thrombotic Complications in Congenital Afibrinogenemia: A Pathophysiological and Management Dilemma. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 577-582.	2.7	16
230	Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic workâ€up. <i>American Journal of Hematology</i> , 2016, 91, E319-20.	4.1	0
231	A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. <i>Haematologica</i> , 2016, 101, 1544-1552.	3.5	72
232	Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion. <i>Leukemia and Lymphoma</i> , 2016, 57, 2685-2688.	1.3	20
233	Clinical impact of small subclones harboring <i>NOTCH1</i> , <i>SF3B1</i> or <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e135-e138.	3.5	34
234	RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications. <i>Haematologica</i> , 2016, 101, 941-950.	3.5	44

#	ARTICLE	IF	CITATIONS
235	Reappraising the timing of transplant for indolent non-Hodgkin lymphomas. Expert Review of Hematology, 2016, 9, 951-964.	2.2	1
236	Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica, 2016, 101, 951-958.	3.5	18
237	The genetics of nodal marginal zone lymphoma. Blood, 2016, 128, 1362-1373.	1.4	147
238	Management of elderly and unfit patients with chronic lymphocytic leukemia. Expert Review of Hematology, 2016, 9, 1165-1175.	2.2	6
239	The antileukemic potential of natural killer cells. Immunotherapy, 2016, 8, 425-434.	2.0	2
240	Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era. Leukemia Research, 2016, 44, 53-60.	0.8	25
241	Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients. Leukemia, 2016, 30, 1615-1619.	7.2	16
242	CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. Leukemia Research, 2016, 41, 36-42.	0.8	41
243	Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program. Leukemia and Lymphoma, 2016, 57, 1716-1718.	1.3	2
244	Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. Oncoimmunology, 2016, 5, e1041701.	4.6	34
245	Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients. Blood, 2016, 128, 1214-1214.	1.4	8
246	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. Blood, 2016, 128, 2038-2038.	1.4	3
247	Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome. Blood, 2016, 128, 2959-2959.	1.4	3
248	Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia. Oncotarget, 2016, 7, 7586-7596.	1.8	13
249	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. Oncotarget, 2016, 7, 20520-20531.	1.8	40
250	Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma. Blood, 2016, 128, 5308-5308.	1.4	0
251	Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification. Blood, 2016, 128, 3240-3240.	1.4	0
252	HIF-1 $\alpha$ Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. Blood, 2016, 128, 305-305.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study. <i>Blood</i> , 2016, 128, 5589-5589.	1.4	0
254	Management of adult Ph-positive acute lymphoblastic leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 406-413.	2.5	33
255	Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. <i>Blood</i> , 2015, 126, 1925-1929.	1.4	154
256	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	1.4	197
257	The pan-class I phosphatidylinositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. <i>Scientific Reports</i> , 2015, 5, 18137.	3.3	28
258	Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. <i>American Journal of Hematology</i> , 2015, 90, E181-2.	4.1	2
259	Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. <i>Haemophilia</i> , 2015, 21, 496-501.	2.1	58
260	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 818-826.	2.8	37
261	Enteropathy-associated T-cell lymphoma in childhood: a case report and review of the literature. <i>Leukemia and Lymphoma</i> , 2015, 56, 2743-2746.	1.3	2
262	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 57-66.	10.7	1,031
263	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. <i>Leukemia</i> , 2015, 29, 1360-1365.	7.2	57
264	The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBP $\beta$ . <i>Leukemia</i> , 2015, 29, 2442-2445.	7.2	27
265	Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. <i>Haematologica</i> , 2015, 100, e10-e13.	3.5	35
266	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	27.0	281
267	Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. <i>Leukemia Research</i> , 2015, 39, 1382-1388.	0.8	30
268	The Kr $\mu$ ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , 2015, 29, 503-507.	7.2	84
269	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. <i>Oncotarget</i> , 2015, 6, 32089-32103.	1.8	36
270	NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. <i>Oncotarget</i> , 2015, 6, 42569-42574.	1.8	35



#	ARTICLE	IF	CITATIONS
271	Early Response Does Not Impact on the Long-Term Outcome of Children and Adolescents with Chronic Myeloid Leukemia Treated with High-Dose Imatinib. the Italian Experience. <i>Blood</i> , 2015, 126, 2788-2788.	1.4	0
272	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	4.1	104
273	Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014, 28, 642-648.	7.2	57
274	Changes in the Treatment Landscape for Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 273-274.	27.0	13
275	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. <i>Leukemia Research</i> , 2014, 38, 198-203.	0.8	4
276	Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. <i>Leukemia Research</i> , 2014, 38, 194-197.	0.8	23
277	Cytomegalovirus in Bone Marrow Cells Correlates with Cytomegalovirus in Peripheral Blood Leukocytes. <i>Journal of Clinical Microbiology</i> , 2014, 52, 2183-2185.	3.9	4
278	CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. <i>Blood</i> , 2014, 123, 3677-3679.	1.4	22
279	Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. <i>Haematologica</i> , 2014, 99, 1248-1254.	3.5	57
280	Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial. <i>Blood</i> , 2014, 124, 150-150.	1.4	4
281	Final Results from the Phase IIa Study of the Anti-CXCL12 Spiegelmer® Olaptosed Pegol (NOX-A12) in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2111-2111.	1.4	4
282	First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients. <i>Blood</i> , 2014, 124, 797-797.	1.4	11
283	Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7005-7005.	1.6	12
284	Phase 3 study of oral lenalidomide as maintenance therapy for patients with B-cell chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7125-TPS7125.	1.6	1
285	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. <i>ELife</i> , 2014, 3, .	6.0	43
286	Independent Prognostic Impact of CD15 for Achievement of Complete Remission in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3687-3687.	1.4	0
287	Clinical Features and Prognostic Factors in Solitary Plasmacytoma: A Single Center Retrospective Study. <i>Blood</i> , 2014, 124, 3455-3455.	1.4	0
288	Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2014, 124, 1326-1326.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Bendamustine and Dexamethasone Is an Effective Salvage Regimen for Patient with Advanced Multiple Myeloma in a Home Care Unit Program. <i>Blood</i> , 2014, 124, 5753-5753.	1.4	0
290	Small Subclones Harboring NOTCH1, SF3B1 or BIRC3 Mutations Are Clinically Irrelevant in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 295-295.	1.4	1
291	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , 2013, 5, 826-837.	5.2	105
292	Clinical implications of the molecular genetics of chronic lymphocytic leukemia. <i>Haematologica</i> , 2013, 98, 675-685.	3.5	65
293	Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia. <i>PLoS Genetics</i> , 2013, 9, e1003997.	3.5	110
294	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. <i>Haematologica</i> , 2013, 98, 1702-1710.	3.5	121
295	PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study. <i>Blood</i> , 2013, 122, 405-405.	1.4	11
296	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013, 122, 770-770.	1.4	2
297	Rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by sequential use of nilotinib and imatinib: A GIMEMA protocol LAL 1408.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7025-7025.	1.6	1
298	Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients. <i>Blood</i> , 2013, 122, 2026-2026.	1.4	0
299	Modulation Of The Glycolytic Metabolism In Acute Myeloid Leukemia Cells. <i>Blood</i> , 2013, 122, 5045-5045.	1.4	0
300	FLT3-ITD Internal Tandem Duplication Confers Poor Prognosis In Patients With Acute Promyelocytic Leukemia Treated With The AIDA Protocols. Long-Term Follow-Up Analysis. <i>Blood</i> , 2013, 122, 1336-1336.	1.4	0
301	Splenectomy Is Still a Valid Option For Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2013, 122, 5129-5129.	1.4	0
302	Management of adult patients with Philadelphia positive acute lymphoblastic leukemia. <i>Rinsho Ketsueki/the Japanese Journal of Clinical Hematology</i> , 2013, 54, 1828-37.	0.5	0
303	The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. <i>Leukemia Supplements</i> , 2012, 1, S26-S28.	0.1	3
304	BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6531-6531.	1.6	0
305	B-Cell Receptor Configuration and Adverse Cytogenetics Are Associated with Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1780-1780.	1.4	0
306	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 2305-2315.	27.0	949

#	ARTICLE	IF	CITATIONS
307	Caring for patients with haematological malignancies. <i>Lancet Oncology</i> , The, 2011, 12, 928-929.	10.7	2
308	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome- <i>+</i> acute lymphoblastic leukemia. <i>Blood</i> , 2011, 118, 6521-6528.	1.4	395
309	Acute lymphoblastic leukemia: age and biology. <i>Mental Illness</i> , 2011, 3, 2.	0.8	6
310	The European Hematology Association: strengthening hematology in Europe and beyond. <i>Expert Review of Hematology</i> , 2011, 4, 133-136.	2.2	0
311	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011, 118, 294-294.	1.4	6
312	Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,. <i>Blood</i> , 2011, 118, 3564-3564.	1.4	1
313	Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. <i>Annals of Oncology</i> , 2010, 21, 1870-1876.	1.2	119
314	Incidence and Predictors of Early Treatment-Related Mortality In Pediatric Acute Lymphoblastic Leukemia In Baghdad (Iraq). <i>Blood</i> , 2010, 116, 2132-2132.	1.4	1
315	A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis. <i>Blood</i> , 2010, 116, 2462-2462.	1.4	17
316	GIMEMA-AIEOP AIDA Protocols for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) In Children: Analysis of 247 Patients Enrolled In Two Sequential Italian Multicenter Trials. <i>Blood</i> , 2010, 116, 871-871.	1.4	7
317	Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in <i>BCR-ABL1</i> -positive acute lymphoblastic leukemia (ALL) patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 7049-7049.	1.6	0
318	Acute Erythroid Leukemia: A Distinctive Subtype of AML? Outcome and Prognostic Factors in Comparison with Non-M6 AML. The Gimema Experience.. <i>Blood</i> , 2009, 114, 1019-1019.	1.4	0
319	CRLF2/JAK Signaling in Adult and Pediatric Acute Lymphoblastic Leukemia Is Highly Similar to BCR/ABL.. <i>Blood</i> , 2009, 114, 3461-3461.	1.4	0
320	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome- <i>+</i> positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. <i>Blood</i> , 2007, 109, 3676-3678.	1.4	336
321	714 CONTROLLED - RELEASE (CR) OXYCODONE FOR THE TREATMENT OF IATROGENIC NEUROPATHIC PAIN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES. <i>European Journal of Pain</i> , 2006, 10, S186b-S186.	2.8	0
322	A broad and integrated diagnostic work-up for a modern management of Acute Lymphoblastic Leukemia (ALL). <i>Hematology</i> , 2005, 10, 55-62.	1.5	1
323	IgVH mutations in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2005, 90, 434-5.	3.5	0
324	Breast Cancer Resistance Protein (BCRP) in Adult Acute Lymphoblastic Leukemia Patients.. <i>Blood</i> , 2004, 104, 1897-1897.	1.4	0

#	ARTICLE	IF	CITATIONS
325	Identification of a LOH Region on Chromosome 9p Associated with a Specific Gene Expression Signature in Adult B-Lineage ALL through Integration of High Density Microarray Expression and SNP Analyses.. Blood, 2004, 104, 1119-1119.	1.4	0